Article History


Historical News Related to Your Article
Aevolve Announces Support for Rare Disease Research

Aevolve Announces Support for Rare Disease ResearchAevolve, a medical innovation platform, today announced that it will be making support for rare disease research a top priority in its blockchain-powered accelerator, which provides a pathway for alternative funding of medical innovations using token securitization and a direct marketplace for treatment reservations. [...]BioSpace - Research23 Aug 2019

AC Immune Announces Research Collaboration with University of Pennsylvania Focusing on Pathogenic Protein TDP-43 in Neurodegenerative DiseasesAC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, announced a research partnership with leading scientists in the Perelman School of Medicine at the University of Pennsylvania focused on studying the pathological mechanisms of TDP-43 misfolding and aggregation. [...]BioSpace - Research12 Aug 2019

Gain Therapeutics SA Announces Award Notification of a €1.4M Grant Support From Eurostars-2 Together With the Institute for Research in Biomedicine and Neuro-Sys SAS After Having Scored 2nd Among 325 Eligible ApplicationsGain Therapeutics SA announced that together with Dr. Maurizio Molinari from the Institute for Research in Biomedicine, Bellinzona (Switzerland) affiliated to the Università della Svizzera italiana (USI) and Neuro-Sys SAS in Gardanne (France), it has received funding support from Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency. [...]BioSpace - Research23 Jul 2019

Spring Bank Announces Research Agreement with The National Institute of Allergy and Infectious Diseases to Evaluate HBV Antisense Oligonucleotide CompoundsSpring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), today announced that it has entered into a research agreement with The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to evaluate Spring Bank’s hepatitis B virus (HBV) antisense oligonucleotide compounds. [...]BioSpace - Research18 Jul 2019

Inscopix Announces Research Collaboration To Pursue New Approach for Development of Therapies for Chronic PainInscopix today announced a new research collaboration with Biogen to research and develop a new class of therapies for chronic pain.BioSpace - Research15 Jul 2019

Gilead and Galapagos Enter Into Transformative Research and Development CollaborationGilead Sciences, Inc. and Galapagos NV announced that they have entered into a 10-year global research and development collaboration.BioSpace - Research14 Jul 2019

Gilead and Carna Biosciences Announce Research and Development Collaboration to Develop Novel Immuno-Oncology TherapiesGilead Sciences, Inc. and Carna Biosciences Inc. announced that the companies have entered into a research and development collaboration to develop and commercialize small molecule compounds in immuno-oncology and to access Carna’s proprietary lipid kinase drug discovery platform.BioSpace - Research25 Jun 2019

Prometheus Research and HealthVerity Announce Selection by Epilepsy Foundation to Develop a Community Data ResourceEpilepsy Foundation, the largest national epilepsy advocacy organization, has selected the team of Prometheus Research and HealthVerity to develop a new data infrastructure capable of creating the largest hub of repurposable data on epilepsy in the world.BioSpace - Research24 Jun 2019

Spero Therapeutics and the Gates Medical Research Institute Collaborate on Tuberculosis TreatmentThere are currently no oral antibiotics specifically approved for use to treat pulmonary NTM infections. If successfully developed, SPR720 has the potential to address an important unmet need as the first oral antibiotic.BioSpace - Research20 Jun 2019

Spero Therapeutics Announces Collaboration with Bill & Melinda Gates Medical Research Institute to Develop SPR720 for TuberculosisSpero Therapeutics, Inc. announced that it entered into a collaboration with the Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis, an indication that is designated as a critical concern by the World Health Organization. [...]BioSpace - Research20 Jun 2019

Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare DiseasesScope of the collaboration expands to include up to 12 rare disease targets and includes Arcturus nucleic acid technologies to enable mRNA, DNA, and siRNA therapeuticsBioSpace - Research19 Jun 2019

Dyne Therapeutics Announces Support for END-DM1 Natural History Study of Patients with Myotonic Dystrophy Type 1 (DM1)Study sponsored by Myotonic Dystrophy Clinical Research Network will advance understanding of disease progression and enable development of clinical outcome assessmentsBioSpace - Research17 Jun 2019

AbCellera Announces Therapeutic Antibody Discovery Collaboration with Gilead in Infectious DiseaseAbCellera, a leader in therapeutic antibody discovery from natural immune systems, announced it has entered into an agreement with Gilead Sciences to support the discovery of therapeutic antibody candidates for infectious diseases.BioSpace - Research13 Jun 2019

Evotec Receives $23.8 Million Grant from Gates Foundation for Tuberculosis Research“We are honored to join with The Bill & Melinda Gates Foundation to fight tuberculosis, one of the world’s most deadly infectious diseases,” stated Werner Lanthaler, Evotec’s chief executive officer.BioSpace - Research11 Jun 2019

Boston Biomedical, Inc. Announces the Continuation of the Phase 3 CanStem303C Study of Napabucasin in Patients with Advanced Colorectal Cancer Following Interim AnalysisBoston Biomedical, Inc. announced the continuation of the CanStem303C study evaluating the safety and efficacy of investigational agent napabucasin when given in combination with FOLFIRI with or without bevacizumab in patients with advanced colorectal cancer.BioSpace - Research07 Jun 2019

ARS Pharmaceuticals Announces Results from EPI-04 Clinical Study of ARS-1 Intranasal Epinephrine Spray in Allergy Patients with Allergic RhinitisResults demonstrate rapid epinephrine absorption with an overall pharmacokinetic profile comparable to epinephrine injection in allergy-induced patientsBioSpace - Research04 Jun 2019

Amicus and Penn Broaden Gene Therapy Collaboration to Include 12 More Rare DiseasesThe deal broadens their work together from three to six programs for rare genetic diseases, as well as rights to collaborative R&D of novel gene therapies for lysosomal disorders and 12 additional rare diseases.BioSpace - Research29 May 2019

Bayer and Foundation Medicine announce global collaboration to develop next-generation sequencing (NGS)-based companion diagnostics in oncologyBayer AG and Foundation Medicine, Inc. announced a global collaboration for the development and commercialization of NGS-based companion diagnostics.BioSpace - Research29 May 2019

Amgen Joins With Community Oncology Networks For New Research CollaborationAmgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiative to enhance access by community centers to innovative oncology clinical researchBioSpace - Research28 May 2019

BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and EuropeBioMarin Pharmaceutical Inc. announced that its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A achieved pre-specified clinical criteria for regulatory review in the U.S. and Europe.BioSpace - Research28 May 2019

GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain TherapiesGBS Global Biopharma's proprietary neuropathic pain therapies are orally-delivered, time-released nanoparticles containing myrcene and other cannabinoid-based ingredientsBioSpace - Research28 May 2019

Calidi Biotherapeutics Announces A Collaborative Study With The National Institutes Of Health (NIH) On The Therapeutic Potential Of Oncolytic Viruses Delivered By Mesenchymal Stem CellsCalidi Biotherapeutics, Inc. announced their ongoing scientific collaboration with David F. Stroncek, M.D., Chief, Cell Therapy Section at the Department of Transfusion Medicine, National Institutes of Health (NIH) to jointly study the impact of different stem cell carriers on the therapeutic potential of oncolytic viruses in the treatment of cancer. [...]BioSpace - Research28 May 2019

Sensorion Announces the Signature of a Partnership Framework Agreement with Institut Pasteur on Gene Therapy Programs Targeting Hearing LossThis agreement defines an exclusive option to obtain licences for joint programs including Otoferlin & Usher Type 1 and preference rights on the research pipeline in the field of genetic disorders of the inner ear in order to set up future collaborationsBioSpace - Research27 May 2019

NeoImmuneTech Announces that the FDA has Allowed the Center for Cancer Research, National Cancer Institute to Proceed with an Investigational New Drug Application to Initiate a Clinical Trial for Hyleukin-7™NeoImmuneTech, Inc. announced that the U.S. Food and Drug Administration has allowed the Center for Cancer Research, National Cancer Institute to proceed with an Investigational New Drug application application for Hyleukin-7™, a long acting T cell amplifier, to begin a clinical trial aiming to enhance the immune reconstitution and vaccine responses in elderly cancer survivors following chemotherapy. [...]BioSpace - Research24 May 2019

APRINOIA Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson's ResearchAPRINOIA Therapeutics announces that it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) for the development of alpha-synuclein PET imaging tracers.BioSpace - Research23 May 2019

Trovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD™ in Models of Colorectal CancerONZEALD is currently being evaluated in a Phase 3 trial in patients with metastatic breast cancer and brain metastasesBioSpace - Research23 May 2019

McCord Research Makes Major Progress Towards Asthma Clinical Trials with Key Broccoli CompoundMcCord Research has recently focused investigations on a key broccoli compound, sulforaphane, in relation to its effects on asthma according to D. Elizabeth McCord, PhD, the company's CEO.BioSpace - Research22 May 2019

CureVac Enters into an Exclusive Sponsored Research Agreement for Discovery Research in mRNA-based Eye Therapy Candidates with the Schepens Eye Research Institute, Harvard Medical School and the Massachusetts Eye and Ear InfirmaryCureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced it has entered into a sponsored research agreement (“SRA”) with Schepens Eye Research Institute of Massachusetts Eye and Ear, a teaching hospital of Harvard Medical School, for discovery research in mRNA-based eye therapy candidates. [...]BioSpace - Research20 May 2019

Florida Research Institute & Echosens Present Research Studies at May 2019 Digestive Disease Week: Highlights Value of Non-Invasive Screening for Fatty Liver DiseaseEchosens, an innovative high-technology company offering the FibroScan family of products, has funded an ongoing study conducted by the Florida Research Institute, a global leader in disease researchBioSpace - Research20 May 2019

Quanterix Announces $50,000 in Grants to Support Promising Oncology ResearchQuanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced a call for proposals for a new Accelerator Grant ProgramBioSpace - Research16 May 2019

Intec Pharma Announces Research Collaboration Agreement With MerckIntec Pharma Ltd. announces it has entered into an agreement with Merck, known as MSD outside the United States and Canada, to explore using the Accordion Pill® platform for an undisclosed development program.BioSpace - Research16 May 2019

Concert Pharmaceuticals Announces Initiation of New Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia AreataConcert Pharmaceuticals, Inc. announced that it has initiated a second open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata.BioSpace - Research16 May 2019

Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug CandidatesMatinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that they have entered into a research collaboration with ViiV Healthcare,BioSpace - Research15 May 2019

Muscular Dystrophy Association Awards 26 Grants Totaling More Than $7.5 Million for Neuromuscular Disease ResearchThe Muscular Dystrophy Association (MDA) announced today the awarding of 26 new MDA grants totaling more than $7.5 million toward research focused on a variety of rare neuromuscular diseasesBioSpace - Research14 May 2019

Global Addison’s Disease Therapeutics Market 2019-2023 | Expanding Research into Development of Regenerative Therapy | TechnavioThe global Addison’s disease therapeutics market is expected to post a CAGR of close to 4%% during the period 2019-2023, according to the latest market research report by Technavio.BioSpace - Research13 May 2019

Aethlon Medical Announces Collaboration With Prostate On-Site Project (POP), Host Of The Jerry Colangelo Sports Legend Golf Classic, To Engage With Participants For CTE StudiesCompany also announces issuance of European patent covering TAUSOME™ technologyBioSpace - Research13 May 2019

CardioFocus Announces Impressive Results From Pivotal Confirmatory Study With The Breakthrough HeartLight® X3 SystemCardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3 System for the treatment of AFibBioSpace - Research10 May 2019


Enabled by smarttopics.mimyr.com
Refreshed on 24 Aug 2019


© 2018-Present EZINTEG LLC - Terms of use -